Volume 7 Supplement 1

16th International Symposium on HIV and Emerging Infectious Diseases

Open Access

Duration of antiretroviral regimens in treatment-experienced patients in clinical practice

  • Vicente Escudero Vilaplana1Email author,
  • Sergio Plata Paniagua1,
  • Nicolas Trovato Lopez1,
  • Isabel Castillo Romera1,
  • Arantza Ais Larisgoitia1,
  • Jose Maria Bellon Cano1 and
  • Maria Sanjurjo Saez1
Retrovirology20107(Suppl 1):P166

DOI: 10.1186/1742-4690-7-S1-P166

Published: 11 May 2010

Background

Antiretroviral regimens (ART) with few changes due to side effects or treatment failure are preferred. Therefore, duration of treatment and persistence (defined as continuing therapy or not) are useful measures of success of ART. We studied duration of ART in treatment-experienced patients (TEP) and analyzed how a history of non-adherence affects it.

Methods

In September 2009, we conducted a retrospective, observational study of adult TEP whose ART was switched between 01/05/2008 and 30/04/2009. We used pharmacy records to select all patients who switched an ART containing darunavir, raltegravir, maraviroc, and/or etravirine and patients who had switched regimens not containing these drugs (1:1) on the same day. The primary endpoint was duration of treatment from inclusion until the last refill, or until the first refill of a new regimen. Patients were classified as non-adherent if they had collected less than 90% of the doses needed during the year before inclusion. Control variables were viral load (VL), CD4 count at inclusion, and time since first ART regimen (tART). Persistence was estimated using Kaplan-Meier plots. Groups were compared using the log-rank test and a Cox regression model was adjusted for control variables.

Results

We included 146 patients (66.4% men); mean age 45.4 years. Baseline clinical characteristics (median [IQR]) were VL = 50 (50-7331) copies/mL, CD4 count = 345 (184-540) cells/μL, tART = 10.0 (4.2-10.7) years. Etravirine, maraviroc, and/or raltegravir were administered to 45.9% of patients, and efavirenz to 21.9%.

Persistence (95% CI) at 6 and 12 months was 77.9% (70.9%-84.9%) and 65.9% (55.5%-76.5%), respectively. Mean duration of treatment was 342 (15) days. Non-adherence was observed in 29.3% (21.2%-37.3%). Persistence at 12 months for adherent and non-adherent patients was 71.7% (58.1%-85.3%) vs 59.0% (32.2%-84.8%), respectively (p = 0.342). There were no differences in persistence adjusted for control variables (HR, 0.774 [0.343-1.750]; p = 0.539).

After a median 281 days of follow-up, 24.7% (17.7-31.6) had stopped or changed ART because of toxicity (52.8%), treatment failure (19.4%), or simplification (8.3%).

Discussion

Our results for persistence are similar to published data for naïve patients and toxicity is also the main reason for switching treatment. A history of non-adherence has less effect on persistence than expected.

Authors’ Affiliations

(1)
Hospital General Universitario Gregorio Marañon

Copyright

© Vilaplana et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement